May 5, 2020 10:19 AM EDTUpdated 05:11 PM
R&D

Ake­bia touts da­ta for two PhI­II stud­ies, set­ting up show­down with As­traZeneca, Fi­bro­Gen

Jason Mast

Editor

Three months af­ter their com­mer­cial part­ner Vi­for dropped $100 mil­lion on a pri­or­i­ty re­view vouch­er for their ex­per­i­men­tal ane­mia drug, Ake­bia tout­ed the re­sults …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times